Статья
Тиазидные и тиазидоподобные диуретики в терапии артериальной гипертензии
Статья представляет собой аналитический обзор клинических исследований, посвященных эффективности и безопасности тиазидных и тиазидоподобных диуретиков (ТД) в лечении пациентов с артериальной гипертензией. В работе проводится сопоставление роли диуретиков в современных клинических рекомендациях по контролю артериального давления, оцениваются метаболические эффекты ТД в сравнительном аспекте.
1. Чазова И.Е., Ратова Л.Г., Бойцов С.А., Небиеридзе Д.В., Карпов Ю.А., Белоусов Ю.Б. и др. Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии. 2010;3:5–26
2. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology. 2018;71(19):e127–248. DOI: 10.1016/j.jacc.2017.11.006
3. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021–104. DOI: 10.1093/eurheartj/ehy339
4. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: metaanalysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338(may19 1):b1665–b1665. DOI: 10.1136/bmj.b1665
5. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J et al. Effects of Different Blood Pressure–Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus: Results of Prospectively Designed Overviews of Randomized Trials. Archives of Internal Medicine. 2005;165(12):1410–9. DOI: 10.1001/archinte.165.12.1410
6. Turnbull F. Effects of different bloodpressurelowering regimens on major cardiovascular events: results of prospectivelydesigned overviews of randomised trials. The Lancet. 2003;362(9395):1527–35. DOI: 10.1016/S01406736(03)147393
7. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in HighRisk Hypertensive Patients Randomized to AngiotensinConverting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA: The Journal of the American Medical Association. 2002;288(23):2981–97. DOI: 10.1001/jama.288.23.2981
8. Cobiac LJ, Magnus A, Lim S, Barendregt JJ, Carter R, Vos T. Which Interventions Offer Best Value for Money in Primary Prevention of Cardiovascular Disease? PLoS ONE. 2012;7(7):e41842. DOI: 10.1371/journal.pone.0041842
9. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH et al. Health Outcomes Associated With Various Antihypertensive Therapies Used as FirstLine Agents: A Network Metaanalysis. JAMA. 2003;289(19):2534–44. DOI: 10.1001/jama.289.19.2534
10. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202(11):1028–34. PMID: 4862069
11. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213(7):1143–52. PMID: 4914579
12. Helgeland A, Leren P. Oslo Study: Treatment of Mild Hypertension. Nephron. 1987;47(1):108–10. DOI: 10.1159/000184565
13. Materson BJ, Cushman WC, Goldstein G, Reda DJ, Freis ED, Ramirez EA et al. Treatment of hypertension in the elderly: I. Blood pressure and clinical changes. Results of a Department of Veterans Affairs Cooperative Study. Hypertension (Dallas, Tex.: 1979). 1990;15(4):348–60. PMID: 2318517
14. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V et al. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in HighRisk Patients. New England Journal of Medicine. 2008;359(23):2417–28. DOI: 10.1056/NEJMoa0806182
15. Jamerson KA, Devereux R, Bakris GL, Dahlöf B, Pitt B, Velazquez EJ et al. Efficacy and Duration of Benazepril Plus Amlodipine or Hydrochlorthiazide on 24Hour Ambulatory Systolic Blood Pressure Control. Hypertension. 2011;57(2):174–9. DOI: 10.1161/HYPERTENSIONAHA.110.159939
16. Messerli FH, Makani H, Benjo A, Romero J, Alviar C, Bangalore S. Antihypertensive Efficacy of Hydrochlorothiazide as Evaluated by Ambulatory Blood Pressure Monitoring. Journal of the American College of Cardiology. 2011;57(5):590–600. DOI: 10.1016/j.jacc.2010.07.053
17. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipidlowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000;283(15):1967–75. PMID: 10789664
18. Siragy HM. Major outcomes in highrisk hypertensive patients randomized to angiotensinconverting enzyme inhibitors or calcium channel blocker vs diuretic. The Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT). Current Hypertension Reports. 2003;5(4):293–4. PMID: 12844462
19. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265(24):3255–64. PMID: 2046107
20. Ames RichardP, Hill P. Increase in serumlipids during treatment of hypertension with chlorthalidone. The Lancet. 1976;307(7962):721–3. DOI: 10.1016/S01406736(76)930932
21. Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate WB, Black HR et al. Influence of longterm, lowdose, diureticbased, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine. 1998;158(7):741–51. PMID: 9554680
22. Kreeft JH, Langlois S, Ogilvie RI. Comparative trial of indapamide and hydrochlorothiazide in essential hypertension, with forearm plethysmography. Journal of Cardiovascular Pharmacology. 1984;6(4):622–6. PMID: 6206316
23. Brandao SA, Izar MC, Fischer SM, Santos AO, Monteiro CM, Povoa RM et al. Early Increase in Autoantibodies Against Human Oxidized LowDensity Lipoprotein in Hypertensive Patients After Blood Pressure Control. American Journal of Hypertension. 2010;23(2):208–14. DOI: 10.1038/ajh.2009.214
24. Spence JD, Huff M, Barnett PA. Effects of indapamide versus hydrochlorothiazide on plasma lipids and lipoproteins in hypertensive patients: a direct comparison. The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique. 2000;7(1):32–7. PMID: 10822211
25. PATS Collaborating Group. Poststroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal. 1995;108(9):710–7. PMID: 8575241
26. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D et al. Treatment of Hypertension in Patients 80 Years of Age or Older. New England Journal of Medicine. 2008;358(18):1887–98. DOI: 10.1056/NEJMoa0801369
27. Агеева Н.В., Агеев Ф.Т., Орлова Я.А., Хеймец Г.И., Рогоза А.Н. Влияние тиазидных диуретиков на артериальное давление, реологию крови и жесткость сосудистой стенки у пациентов с АГ: результаты исследования РОНДО (РеОлогические и аНгиопротекторное Действие прОлонгированного индапамида у больных с артериальной гипертонией). Болезни сердца и сосудов. 2008;1:305
28. Mironneau J, Savineau JP, Mironneau C. Compared effects of indapamide, hydrochlorothiazide and chlorthalidone on electrical and mechanical activities in vascular smooth muscle. European Journal of Pharmacology. 1981;75(2–3):109–13. DOI: 10.1016/00142999(81)900686
29. Kooter AJ, Smulders YM. Chlorthalidone better than hydrochlorothiazide in hypertension. Nederlands Tijdschrift Voor Geneeskunde. 2010;154:A1608. PMID: 20456766
30. Tziomalos K, Athyros VG, Mikhailidis DP, Karagiannis A. Hydrochlorothiazide vs. chlorthalidone as the optimal diuretic for the management of hypertension. Current Pharmaceutical Design. 2013;19(21):3766–72. PMID: 23286433
31. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide Versus Chlorthalidone: Evidence Supporting Their Interchangeability. Hypertension. 2004; 43 (1): 4–9. DOI: 10.1161/01.HYP.0000103632.19915.0E
32. Beaumont K, Vaughn DA, Fanestil DD. Thiazide diuretic drug receptors in rat kidney: identification withmetolazone. Proceedings of the National Academy of Sciences. 1988;85(7):2311–4. DOI: 10.1073/pnas.85.7.2311
33. Sumiye L, Vivian AS, Frisof KB, Podany EC. Potassium loss associated with hydrochlorothiazide versus chlorthalidone. Clinical Therapeutics. 1981;4(4):308–20. PMID: 7332917
34. Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. MetaAnalysis of DoseResponse Relationships for Hydrochlorothiazide, Chlorthalidone, and Bendroflumethiazide on Blood Pressure, Serum Potassium, and Urate. Hypertension. 2012;59(6):1104–9. DOI: 10.1161/HYPERTENSIONAHA.111.190637
35. Baguet JP, Legallicier B, Auquier P, Robitail S. Updated MetaAnalytical Approach to the Efficacy of Antihypertensive Drugs in Reducing Blood Pressure: Clinical Drug Investigation. 2007;27(11):735–53. DOI: 10.2165/0004401120072711000001
36. Musini VM, Nazer M, Bassett K, Wright JM. Blood pressurelowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database of Systematic Reviews. 2014;5:CD003824. DOI: 10.1002/14651858.CD003824.pub2
37. Amery A, Bulpitt C, Schaepdryver AD, Fagard R, Hellemans J, Mutsers A et al. Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly. The Lancet. 1978;311(8066):681–3. DOI: 10.1016/S01406736(78)907973
38. Chrysant SG, Neller GK, Dillard B, Frohlich ED. Effects of Diuretics On Lipid Metabolism in Patients With Essential Hy per tension. Angiolog y. 1976;27(12):707–11. DOI: 10.1177/000331977602701205
39. Pollare T, Lithell H, Berne C. A Comparison of the Effects of Hydrochlorothiazide and Captopril on Glucose and Lipid Metabolism in Patients with Hypertension. New England Journal of Medicine. 1989;321(13):868–73. DOI: 10.1056/NEJM198909283211305
40. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus. New England Journal of Medicine. 2000;342(13):905–12. DOI: 10.1056/NEJM200003303421301
41. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the AngloScandinavian Cardiac Outcomes TrialBlood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. The Lancet. 2005;366(9489):895–906. DOI: 10.1016/S01406736(05)671851
42. Fletcher A, Amery A, Birkenhäger W, Bulpitt C, Clement D, de Leeuw P et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension. 1991;9(3):225–30. PMID: 1851785
43. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension2 study. The Lancet. 1999;354(9192):1751–6. DOI: 10.1016/S01406736(99)103271
44. Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T et al. Outcomes With Nifedipine GITS or CoAmilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hy per tension. 2003;41(3):431–6. D OI: 10.1161/01.HYP.0000057420.27692.AD
45. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet. 2002;359(9311):995–1003. DOI: 10.1016/S01406736(02)080893
46. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Longterm effect of diureticbased therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. The American Journal of Cardiology. 2005;95(1):29–35. DOI: 10.1016/j.amjcard.2004.08.059
47. Barzilay JI, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Black HR et al. LongTerm Effects of Incident Diabetes Mellitus on Cardiovascular Outcomes in People Treated for Hypertension: The ALLHAT Diabetes Extension Study. Circulation: Cardiovascular Quality and Outcomes. 2012;5(2):153–62. DOI: 10.1161/CIRCOUTCOMES.111.962522
48. Zhang X, Zhao Q. Association of ThiazideType Diuretics With Glycemic Changes in Hypertensive Patients: A Systematic Review and MetaAnalysis of Randomized Controlled Clinical Trials. The Journal of Clinical Hypertension. 2016;18(4):342–51. DOI: 10.1111/jch.12679
49. Smith SM, Anderson SD, Wen S, Gong Y, Turner ST, CooperDeHoff RM et al. Lack of Correlation Between ThiazideInduced Hyperglycemia and Hypokalemia: Subgroup Analysis of Results from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. Pharmacotherapy. 2009;29(10):1157–65. DOI: 10.1592/phco.29.10.1157
50. Kobalava ZD, Kotovskaya YV, Moiseev VS. Efficacy and Acceptability of Indapamide Sustained Release in Elderly HighRisk Hypertensive Patients: the ARGUS Study. High Blood Pressure & Cardiovascular Prevention. 2008;15(4):275–82. DOI: 10.2165/015164220081504000007
51. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ. 1992;304(6824):405–12. DOI: 10.1136/bmj.304.6824.405
52. Elliott WJ, Weber RR, Murphy MB. A doubleblind, randomized, placebocontrolled comparison of the metabolic effects of low dose hydrochlorothiazide and indapamide. Journal of Clinical Pharmacology. 1991;31(8):751–7. PMID: 1880234
53. Kieboom BCT, Zietse R, Ikram MA, Hoorn EJ, Stricker BH. Thiazide but not loop diuretics is associated with hypomagnesaemia in the general population. Pharmacoepidemiology and Drug Safety. 2018;27(11):1166–73. DOI: 10.1002/pds.4636
54. Mychka V.B., Chazova I.E. Russian evidencebased medicine – MINOTAUR program: advantages of the retard form of indapamide in the treatment of metabolic syndrome. Consilium Medicum. 2006;8(5):46–50.
55. Ernst ME, Moser M. Use of Diuretics in Patients with Hypertension. New England Journal of Medicine. 2009;361(22):2153–64. DOI: 10.1056/NEJMra0907219
56. Reid IR, Ames RW, OrrWalker BJ, Clearwater JM, Horne AM, Evans MC et al. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. The American Journal of Medicine. 2000;109(5):362–70. DOI: 10.1016/S00029343(00)005106
57. LaCroix AZ. LowDose Hydrochlorothiazide and Preservation of Bone Mineral Density in Older Adults: A Randomized, DoubleBlind, PlaceboControlled Trial. Annals of Internal Medicine. 2000;133(7):516–26. DOI: 10.7326/00034819133720001003000010
58. Schoofs MWCJ, van der Klift M, Hofman A, de Laet CEDH, Herings RMC, Stijnen T et al. Thiazide Diuretics and the Risk for Hip Fracture. Annals of Internal Medicine. 2003;139(6):476–82. DOI: 10.7326/00034819139620030916000010
59. Ayvazian JH, Ayvazian LF. A study of the hyperuricemia induced by hydrochlorothiazide and acetazolamide separately and in combination. Journal of Clinical Investigation. 1961;40(11):1961–6. DOI: 10.1172/JCI104421
60. Leemhuis MP, Struyvenberg A. Significance of hypokalaemia due to diuretics. The Netherlands Journal of Medicine. 1973;16(1):18–28. PMID: 4572424
61. Weidmann P. Metabolic Profile of Indapamide SustainedRelease in Patients with Hypertension: Data from Three Randomised DoubleBlind Studies. Drug Safety. 2001;24(15):1155–65. DOI: 10.2165/0000201820012415000006
62. Gosse P, Sheridan DJ, Zannad F, Dubourg O, Guéret P, Karpov Y et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. Journal of Hypertension. 2000;18(10):1465–75. PMID: 11057435
63. Wu S, Sun L, Zhao H, Wang G, Li Y, Wang L et al. Chronic effects of lowdose hydrochlorothiazide in patients with mild to moderate essential hypertension. Zhonghua Xin Xue Guan Bing Za Zhi. 2006;34(5):396–9. PMID: 16776948
64. Ames RP, Hill P. Elevation of serum lipid levels during diuretic therapy of hypertension. The American Journal of Medicine. 1976;61(5):748–57. DOI: 10.1016/00029343(76)90156X
65. Weir MR, Flack JM, Applegate WB. Tolerability, safety, and quality of life and hypertensive therapy: The case for lowdose diuretics. The American Journal of Medicine. 1996;101(3):83S92S. DOI: 10.1016/S00029343(96)002719
66. Ott SM, LaCroix AZ, Ichikawa LE, Scholes D, Barlow WE. Effect of LowDose Thiazide Diuretics on Plasma Lipids: Results from a DoubleBlind, Randomized Clinical Trial in Older Men and Women. Journal of the American Geriatrics Society. 2003;51(3):340–7. DOI: 10.1046/j.15325415.2003.51107.x
67. Zanchetti A, Crepaldi G, Bond MG, Gallus G, Veglia F, Mancia G et al. Different Effects of Antihypertensive Regimens Based on Fosinopril or Hydrochlorothiazide With or Without Lipid Lowering by Pravastatin on Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of PHYLLIS – A Randomized DoubleBlind Trial. Stroke. 2004;35(12):2807–12. DOI: 10.1161/01.STR.0000147041.00840.59
68. Pottegård A, Hallas J, Olesen M, Svendsen MT, Habel LA, Friedman GD et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. Journal of Internal Medicine. 2017;282(4):322–31. DOI: 10.1111/joim.12629
69. Pottegård A, Pedersen SA, Schmidt SAJ, Hölmich LR, Friis S, Gaist D. Association of Hydrochlorothiazide Use and Risk of Malignant Melanoma. JAMA Internal Medicine. 2018;178(8):1120–2. DOI: 10.1001/jamainternmed.2018.1652
70. Jensen AØ, Thomsen HF, Engebjerg MC, Olesen AB, Sørensen HT, Karagas MR. Use of photosensitising diuretics and risk of skin cancer: a populationbased case–control study. British Journal of Cancer. 2008;99(9):1522–8. DOI: 10.1038/sj.bjc.6604686
71. Schmidt SAJ, Schmidt M, Mehnert F, Lemeshow S, Sørensen HT. Use of antihypertensive drugs and risk of skin cancer. Journal of the European Academy of Dermatology and Venereology. 2015;29(8):1545–54. DOI: 10.1111/jdv.12921
72. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. The Lancet. 2004;363(9426):2022–31. DOI: 10.1016/S01406736(04)164519
73. Dahlöf B, Hansson L, Lindholm LH, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOPHypertension). The Lancet. 1991;338(8778):1281–5. DOI: 10.1016/01406736(91)92589T
74. Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: metaanalysis of randomised trials. BMJ. 2008;336(7653):1121–3. DOI: 10.1136/bmj.39548.738368.BE
75. National Clinical Guideline Centre (UK). Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34. London: Royal College of Physicians (UK); 36 p.
76. Fujiwara W, Izawa H, Ukai G, Yokoi H, Mukaide D, Kinoshita K et al. Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles. Heart and Vessels. 2013;28(3):316–22. DOI: 10.1007/s0038001202465
77. Hamada T, Mizuta E, Kondo T, Hirai M, Yamada K, Kato M et al. Effects of a lowdose antihypertensive diuretic in combination with losartan, telmisartan, or candesartan on serum urate levels in hypertensive patients. Arzneimittelforschung. 2011;60(02):71–5. DOI: 10.1055/s00311296251
78. Okin PM, Hille DA, Kjeldsen SE, Lindholm LH, Edelman JM, Dahlof B et al. Greater Regression of Electrocardiographic Left Ventricular Hypertrophy During Hydrochlorothiazide Therapy in Hypertensive Patients. American Journal of Hypertension. 2010;23(7):786–93. DOI: 10.1038/ajh.2010.65
79. National Institute for Health and Clinical Excellence. Hypertension Management of hypertension in adults in primary care NICE clinical guideline 18. London: Royal College of Physicians (UK);
80. Gupta AK, Arshad S, Poulter NR. Compliance, Safety, and Effectiveness of FixedDose Combinations of Antihypertensive Agents: A MetaAnalysis. Hypertension. 2010;55(2):399–407. DOI: 10.1161/HYPERTENSIONAHA.109.139816
81. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics. 2001;23(8):1296–310. PMID: 11558866